|
1
|
Wald O, Shapira OM and Izhar U:
CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic
roles and therapeutic potential. Theranostics. 3:26–33. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumarakulasinghe NB, van Zanwijk N and Soo
RA: Molecular targeted therapy in the treatment of advanced stage
non-small cell lung cancer (NSCLC). Respirology. 20:370–378. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gu Y, Körbel C, Scheuer C, Nenicu A,
Menger MD and Laschke MW: Tubeimoside-1 suppresses tumor
angiogenesis by stimulation of proteasomal VEGFR2 and Tie2
degradation in a non-small cell lung cancer xenograft model.
Oncotarget. 7:5258–5272. 2016.PubMed/NCBI
|
|
6
|
Yin Y, Chen W, Tang C, Ding H, Jang J,
Weng M, Cai Y and Zou G: NF-κB, JNK and p53 pathways are involved
in tubeimoside-1-induced apoptosis in HepG2 cells with oxidative
stress and G2/M cell cycle arrest. Food Chem Toxicol. 49:3046–3054.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu L, Ma R, Wang Y and Nishino H: Potent
anti-tumor activity and low toxicity of tubeimoside 1 isolated from
Bolbostemma paniculatum. Planta Med. 60:204–208. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartoli Klugman F, Decorti G, Candussio L,
Mallardi F, Grill V, Zweyer M and Baldini L: Effect of ketotifen on
adriamycin toxicity: Role of histamine. Cancer Lett. 39:145–152.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu Y, Wang G, Chen Q, Lin T, Zeng Z, Luo
Q, Liu J and Sun C: Intrinsic apoptotic pathway and G2/M cell cycle
arrest involved in tubeimoside I-induced EC109 cell death. Chin J
Cancer Res. 25:312–321. 2013.PubMed/NCBI
|
|
10
|
Jia G, Wang Q, Wang R, Deng D, Xue L, Shao
N, Zhang Y, Xia X, Zhi F and Yang Y: Tubeimoside-1 induces glioma
apoptosis through regulation of Bax/Bcl-2 and the ROS/Cytochrome
C/Caspase-3 pathway. Onco Targets Ther. 8:303–311. 2015.PubMed/NCBI
|
|
11
|
Xu Y, Chiu JF, He QY and Chen F:
Tubeimoside-1 exerts cytotoxicity in HeLa cells through
mitochondrial dysfunction and endoplasmic reticulum stress
pathways. J Proteome Res. 8:1585–1593. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang P, Yu C, Liu XQ, Ding YB, Wang YX
and He JL: Cytotoxicity of tubeimoside I in human choriocarcinoma
JEG-3 cells by induction of cytochrome c release and apoptosis via
the mitochondrial-related signaling pathway. Int J Mol Med.
28:579–587. 2011.PubMed/NCBI
|
|
13
|
Wang F, Ma RD and Yu LJ: Role of
mitochondria in tubeimoside I-mediated apoptosis in human cervical
carcinoma HeLa cell line. Zhongguo Zhong Yao Za Zhi. 30:1935–1939.
2005.(In Chinese). PubMed/NCBI
|
|
14
|
Lin Y, Xie G, Xia J, Su D, Liu J, Jiang F
and Xu Y: TBMS1 exerts its cytotoxicity in NCI-H460 lung cancer
cells through nucleolar stress-induced p53/MDM2-dependent
mechanism, a quantitative proteomics study. Biochim Biophys Acta.
1864:204–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Xu X and He P: Tubeimoside-1
inhibits proliferation and induces apoptosis by increasing the Bax
to Bcl-2 ratio and decreasing COX-2 expression in lung cancer A549
cells. Mol Med Rep. 4:25–29. 2011.PubMed/NCBI
|
|
16
|
Ebrahimi F, Gopalan V, Smith RA and Lam
AK: miR-126 in human cancers: Clinical roles and current
perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meister J and Schmidt MH: miR-126 and
miR-126*: New players in cancer. ScientificWorldJournal.
10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schober A, Nazari-Jahantigh M, Wei Y,
Bidzhekov K, Gremse F, Grommes J, Megens RT, Heyll K, Noels H,
Hristov M, et al: MicroRNA-126-5p promotes endothelial
proliferation and limits atherosclerosis by suppressing Dlk1. Nat
Med. 20:368–376. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esser JS, Saretzki E, Pankratz F, Engert
B, Grundmann S, Bode C, Moser M and Zhou Q: Bone morphogenetic
protein 4 regulates microRNAs miR-494 and miR-126-5p in control of
endothelial cell function in angiogenesis. Thromb Haemost.
117:734–749. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li HY, Zhao X, Liu YZ, Meng Z, Wang D,
Yang F and Shi QW: Plasma microRNA-126-5p is associated with the
complexity and severity of coronary artery disease in patients with
stable angina pectoris. Cell Physiol Biochem. 39:837–846. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ladeiro Y, Couchy G, Balabaud C,
Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J:
MicroRNA profiling in hepatocellular tumors is associated with
clinical features and oncogene/tumor suppressor gene mutations.
Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Du YY, Lin YF, Chen YT, Yang L,
Wang HJ and Ma D: The cell growth suppressor, mir-126, targets
IRS-1. Biochem Biophys Res Commun. 377:136–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho WC, Chow AS and Au JS: Restoration of
tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung
adenocarcinoma patients with epidermal growth factor receptor
mutation. Eur J Cancer. 45:2197–2206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Felli N, Felicetti F, Lustri AM, Errico
MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F,
Biffoni M, et al: miR-126&126* restored expressions play a
tumor suppressor role by directly regulating ADAM9 and MMP7 in
melanoma. PLoS One. 8:e568242013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dvorak HF: Vascular permeability
factor/vascular endothelial growth factor: A critical cytokine in
tumor angiogenesis and a potential target for diagnosis and
therapy. J Clin Oncol. 20:4368–4380. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Millauer B, Wizigmann-Voos S, Schnürch H,
Martinez R, Møller NP, Risau W and Ullrich A: High affinity VEGF
binding and developmental expression suggest Flk-1 as a major
regulator of vasculogenesis and angiogenesis. Cell. 72:835–846.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zeng H, Dvorak HF and Mukhopadhyay D:
Vascular permeability factor (VPF)/vascular endothelial growth
factor (VEGF) peceptor-1 down-modulates VPF/VEGF
receptor-2-mediated endothelial cell proliferation, but not
migration, through phosphatidylinositol 3-kinase-dependent
pathways. J Biol Chem. 276:26969–26979. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roskoski R Jr: Vascular endothelial growth
factor (VEGF) signaling in tumor progression. Crit Rev Oncol
Hematol. 62:179–213. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koch S and Claesson-Welsh L: Signal
transduction by vascular endothelial growth factor receptors. Cold
Spring Harb Perspect Med. 2:a0065022012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen P, Zhu J, Liu DY, Li HY, Xu N and Hou
M: Over-expression of survivin and VEGF in small-cell lung cancer
may predict the poorer prognosis. Med Oncol. 31:7752014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ferrara N: The role of vascular
endothelial growth factor in pathological angiogenesis. Breast
Cancer Res Treat. 36:127–137. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mattern J, Koomägi R and Volm M:
Association of vascular endothelial growth factor expression with
intratumoral microvessel density and tumour cell proliferation in
human epidermoid lung carcinoma. Br J Cancer. 73:931–934. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brown LF, Berse B, Jackman RW, Tognazzi K,
Manseau EJ, Dvorak HF and Senger DR: Increased expression of
vascular permeability factor (vascular endothelial growth factor)
and its receptors in kidney and bladder carcinomas. Am J Pathol.
143:1255–1262. 1993.PubMed/NCBI
|
|
35
|
Brown LF, Berse B, Jackman RW, Tognazzi K,
Guidi AJ, Dvorak HF, Senger DR, Connolly JL and Schnitt SJ:
Expression of vascular permeability factor (vascular endothelial
growth factor) and its receptors in breast cancer. Hum Pathol.
26:86–91. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Seto T, Higashiyama M, Funai H, Imamura F,
Uematsu K, Seki N, Eguchi K, Yamanaka T and Ichinose Y: Prognostic
value of expression of vascular endothelial growth factor and its
flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung
Cancer. 53:91–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu B, Peng XC, Zheng XL, Wang J and Qin
YW: miR-126 restoration down-regulate VEGF and inhibit the growth
of lung cancer cell lines in vitro and in vivo. Lung Cancer.
66:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fearnley GW, Odell AF, Latham AM, Mughal
NA, Bruns AF, Burgoyne NJ, Homer-Vanniasinkam S, Zachary IC,
Hollstein MC, Wheatcroft SB and Ponnambalam S: VEGF-A isoforms
differentially regulate ATF-2-dependent VCAM-1 gene expression and
endothelial-leukocyte interactions. Mol Biol Cell. 25:2509–2521.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shankar S, Ganapathy S, Hingorani SR and
Srivastava RK: EGCG inhibits growth, invasion, angiogenesis and
metastasis of pancreatic cancer. Front Biosci. 13:440–452. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kaneshiro T, Morioka T, Inamine M, Kinjo
T, Arakaki J, Chiba I, Sunagawa N, Suzui M and Yoshimi N:
Anthraquinone derivative emodin inhibits tumor-associated
angiogenesis through inhibition of extracellular signal-regulated
kinase 1/2 phosphorylation. Eur J Pharmacol. 553:46–53. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu HZ, Yu C, Yang Z, He JL, Chen WJ, Yin
J, Li WM, Liu HT and Wang YX: Tubeimoside I sensitizes cisplatin in
cisplatin-resistant human ovarian cancer cells (A2780/DDP) through
down-regulation of ERK and up-regulation of p38 signaling pathways.
Mol Med Rep. 4:985–992. 2011.PubMed/NCBI
|
|
42
|
Dias S, Hattori K, Zhu Z, Heissig B, Choy
M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, et al: Autocrine
stimulation of VEGFR-2 activates human leukemic cell growth and
migration. J Clin Invest. 106:511–521. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tian Y, Xie Q, Tian Y, Liu Y, Huang Z, Fan
C, Hou B, Sun D, Yao K and Chen T: Radioactive ¹25I seed
inhibits the cell growth, migration, and invasion of nasopharyngeal
carcinoma by triggering DNA damage and inactivating VEGF-A/ERK
signaling. PLoS One. 8:e740382013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu Y, Qiao Y, Hu C, Liu L, Zhou L, Liu B,
Chen H and Jiang X: VEGFR2 inhibition by RNA interference affects
cell proliferation, migration, invasion, and response to radiation
in Calu-1 cells. Clin Transl Oncol. 18:212–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Santos SC and Dias S: Internal and
external autocrine VEGF/KDR loops regulate survival of subsets of
acute leukemia through distinct signaling pathways. Blood.
103:3883–3889. 2004. View Article : Google Scholar : PubMed/NCBI
|
